{
    "nct_id": "NCT04409262",
    "official_title": "A Phase III, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Patients With Severe COVID-19 Pneumonia",
    "inclusion_criteria": "Inclusion Criteria\n\n* Hospitalized with COVID-19 pneumonia confirmed per a positive polymerase chain reaction (PCR) of any specimen (e.g., respiratory, blood, urine, stool, other bodily fluid) and evidenced by chest X-ray or CT scan\n* Requiring more than 6 L/min supplemental oxygen to maintain SpO2 > 93%\n* Agrees to not participate in another clinical trial for the treatment of COVID-19 while participating in this study\n\nExclusion Criteria\n\n* Known severe allergic reactions to tocilizumab or other monoclonal antibodies\n* Known hypersensitivity to remdesivir, the metabolites, or formulation excipients\n* Active tuberculosis (TB) infection\n* Suspected active bacterial, fungal, viral, or other infection (besides COVID-19)\n* In the opinion of the investigator, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments\n* Treatment with immunosuppressive or immunomodulatory therapy (including tocilizumab) within the past 3 months\n* Concurrent treatment with other agents with actual or possible direct-acting antiviral activity against SARS-CoV-2 within 24 hours prior to study drug dosing. In addition, participants with prior or current treatment with > 2 doses of remdesivir for COVID-19 are excluded\n* Participating in other drug clinical trials\n* Estimated glomerular filtration rate (eGFR) < 30 mL/min (including patients receiving hemodialysis or hemofiltration)\n* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 5 x upper limit of normal (ULN) detected within 24 hours of screening (according to local laboratory reference ranges)\n* Absolute neutrophil count (ANC) < 1000/uL at screening\n* Platelet count < 50,000/uL at screening\n* Body weight < 40 kg\n* Treatment with an investigational drug within 5 half-lives or 30 days (whichever is longer) of randomization\nHealthy volunteers allowed\nMust have minimum age of 12 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}